Buyback and pipeline progress offset by weak reported profit
Buyback plan and first tranche completed The chairman proposed a 10-20 million yuan buyback for equity incentives, and the company then completed a first tranche of about 3.34 million shares for roughly 20 million yuan. Buying its own stock signals confidence and supports the share price.
This is the main capital action driving the stock and shows management's confidence.
Spironolactone tablets pass consistency review Yatai's spironolactone tablets passed China's generic drug quality and efficacy consistency evaluation. This enriches its product pipeline and makes the drug more competitive in hospital procurement, supporting future sales.
It is a concrete regulatory win that improves the product pipeline and competitiveness.
H1 underlying profit turns positive but reported net loss First-half revenue rose 3.6% to 158 million yuan, and non-recurring net profit swung to a 1.4 million yuan gain from a big loss, helped by lower financial expenses and more high-margin non-antibiotic products. But reported net profit was a 440,000 yuan loss, down 100.4% year on year.
It shows the core business improving while the headline reported profit still disappoints, a key counterweight.